Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

20141,754 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 384, Issue 9948, pp. 1109-1117

Field-Weighted Citation Impact: 128.74